Koss Olinger Consulting LLC Sells 88 Shares of Bio-Rad Laboratories, Inc. $BIO

Koss Olinger Consulting LLC trimmed its position in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 1.4% during the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 6,060 shares of the medical research company’s stock after selling 88 shares during the quarter. Koss Olinger Consulting LLC’s holdings in Bio-Rad Laboratories were worth $1,462,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of the company. Oppenheimer Asset Management Inc. raised its holdings in shares of Bio-Rad Laboratories by 1.9% in the 2nd quarter. Oppenheimer Asset Management Inc. now owns 2,871 shares of the medical research company’s stock valued at $693,000 after purchasing an additional 54 shares during the period. State of Alaska Department of Revenue grew its stake in Bio-Rad Laboratories by 2.5% in the 1st quarter. State of Alaska Department of Revenue now owns 2,254 shares of the medical research company’s stock valued at $548,000 after buying an additional 55 shares during the last quarter. UMB Bank n.a. grew its stake in Bio-Rad Laboratories by 89.8% in the 2nd quarter. UMB Bank n.a. now owns 167 shares of the medical research company’s stock valued at $40,000 after buying an additional 79 shares during the last quarter. Blue Trust Inc. grew its stake in Bio-Rad Laboratories by 5.5% in the 2nd quarter. Blue Trust Inc. now owns 1,517 shares of the medical research company’s stock valued at $366,000 after buying an additional 79 shares during the last quarter. Finally, Tokio Marine Asset Management Co. Ltd. grew its stake in Bio-Rad Laboratories by 10.4% in the 1st quarter. Tokio Marine Asset Management Co. Ltd. now owns 994 shares of the medical research company’s stock valued at $242,000 after buying an additional 94 shares during the last quarter. 65.24% of the stock is owned by institutional investors.

Bio-Rad Laboratories Stock Performance

NYSE BIO opened at $339.92 on Monday. The company has a quick ratio of 3.67, a current ratio of 5.12 and a debt-to-equity ratio of 0.17. The company has a market capitalization of $9.20 billion, a P/E ratio of 28.98 and a beta of 0.97. Bio-Rad Laboratories, Inc. has a 12-month low of $211.43 and a 12-month high of $387.99. The firm has a 50-day moving average price of $295.35 and a two-hundred day moving average price of $262.48.

Bio-Rad Laboratories (NYSE:BIO) last posted its quarterly earnings data on Thursday, July 31st. The medical research company reported $2.61 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.93 by $0.68. The firm had revenue of $651.60 million during the quarter, compared to the consensus estimate of $614.82 million. Bio-Rad Laboratories had a net margin of 12.50% and a return on equity of 4.01%. The business’s revenue for the quarter was up 2.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $3.11 EPS. Bio-Rad Laboratories has set its FY 2025 guidance at EPS. Analysts anticipate that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages recently commented on BIO. Wells Fargo & Company upped their price target on shares of Bio-Rad Laboratories from $245.00 to $265.00 and gave the company an “equal weight” rating in a research note on Friday, August 1st. Royal Bank Of Canada upped their price target on shares of Bio-Rad Laboratories from $387.00 to $409.00 and gave the company an “outperform” rating in a research note on Friday, August 1st. Wall Street Zen lowered shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research note on Friday, August 22nd. Weiss Ratings reiterated a “sell (d+)” rating on shares of Bio-Rad Laboratories in a research note on Tuesday, October 14th. Finally, Zacks Research upgraded shares of Bio-Rad Laboratories from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 26th. Three analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $333.50.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.